A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Tuesday, 22 September 2015
AstraZeneca supports crowd sourcing challenge to find new combination therapies for cancer AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer.
Tuesday, 30 June 2015
AstraZeneca and the University of Cambridge announce new joint PhD and clinical research scholarships AstraZeneca and the University of Cambridge announce new joint PhD and clinical research scholarships
Wednesday, 17 June 2015
AstraZeneca to collaborate with Inserm in Type 2 Diabetes and Chronic Kidney Disease studies AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches to type 2 diabetes and Chronic Kidney Disease (CKD). The aim of the collaboration is to advance understanding of the biological mechanisms that underpin these conditions and develop new treatments based on this knowledge.
Wednesday, 17 June 2015
AstraZeneca to collaborate with the University of Michigan to advance treatments for Chronic Kidney Disease AstraZeneca today announced a two-year research collaboration with the University of Michigan to advance the treatment of chronic kidney disease (CKD) through the improved understanding of the disease. The collaboration will tackle the challenging area of identifying novel targets for the treatment of CKD, focusing on the use of patient tissue and validation of preclinical models.
Monday, 11 May 2015
Mene Pangalos elected to the Fellowship of the Academy of Medical Sciences IMED leader one of 48 new fellows recognised for the advancement of medical science in the UK
Tuesday, 21 April 2015
AstraZeneca and Bina collaborate to deploy genomic management solution in R&D AstraZeneca and Bina Technologies, Inc., a member of the Roche Group, today announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Programme and to further develop the Bina Genomic Management Solution (GMS) . AstraZeneca will utilise the Bina GMS to support its development work across its main therapeutic areas of respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease, and oncology.
Thursday, 19 March 2015
AstraZeneca establishes Scientific Review Board to support clinical trial data transparency commitment AstraZeneca today announced the creation of an independent Scientific Review Board to assess requests from external researchers which include patient level data.
Wednesday, 11 March 2015
AstraZeneca to collaborate with key Singapore research organisations in heart failure AstraZeneca today announced a two year collaboration with leading organisations in Singapore, including the Agency for Science, Technology and Research (A*STAR), National University Heart Centre, Singapore (NUHCS) and National University of Singapore, to support research into new therapies for heart failure. In particular, the collaboration will aim to advance understanding of the pathophysiology of heart failure with preserved ejection fraction (HFpEF), a complex syndrome, for which there is currently no effective treatment for patients.
Thursday, 26 February 2015
AstraZeneca to create stand-alone company for small molecule early-stage antibiotic R&D In line with AstraZeneca’s strategy to sharpen its focus on three main therapy areas, the company is changing the structure of its small molecule early-stage anti-infectives research and development.
Wednesday, 25 February 2015
AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class RORγ inhibitors to treat auto-immune diseases AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company, today announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (ROR). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there is currently no safe, effective oral treatment.